ArticleBlood2022
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis.Revista da Associacao Medica Brasileira (1992) · 2024Pooled it
- Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review.Journal of cellular and molecular medicine · 2023Pooled it
- Analysis of factors influencing SARS-CoV-2 infection and outcomes in patients with chronic lymphocytic leukemia during the burst of COVID-19 epidemic.BMC cancer · 2026Article
- Article
- Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era.Blood advances · 2025Article
- COVID-19 and CLL in Sweden: lessons learned?Blood advances · 2025Article
- Article
- Prognostic factors associated with recurrent COVID-19 and impact of SARS-CoV-2 vaccine on patients with chronic lymphocytic leukemia.Frontiers in oncology · 2025Article
- [Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.BMC infectious diseases · 2024Article
- Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.Annals of hematology · 2024Article
- It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia.Blood advances · 2024Article
- Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.Annals of hematology · 2024Article
- Article
- COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant.Cancers · 2024Article
- COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?Acta haematologica · 2024Review
- Management of infections for patient treated with ibrutinib in clinical practice.Frontiers in oncology · 2024Review
- The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.Frontiers in oncology · 2024Article
- Clinical Features and Prognostic Predictors in Patients with Renal Transplant Complicated by SARS-CoV-2 Infection, a Retrospective Single-Center Study.Infection and drug resistance · 2024Article
- Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.Clinical and experimental medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.